Science News for March 16, 2024

RUBY Part 2 trial results: Potentially practice changing results in advanced/recurrent endometrial cancer

The RUBY Part 2 trial shows significant improvement in progression-free survival for patients with primary advanced or recurrent endometrial cancer treated with dostarlimab. Dostarlimab plus niraparib plus carboplatin/paclitaxel demonstrates a role for PARP inhibitor maintenance in improving patient outcomes.

SourceThe GOG Foundation Inc·TypeRandomized controlled/clinical trial·DateMar 16, 2024

Very low calorie diets are safe and acceptable for teenagers with moderate to severe obesity when used short-term and supported by a dietitian, Australian study finds

A new study found that short-term very low calorie diets are safe and acceptable for teenagers with moderate to severe obesity, with most experiencing rapid weight loss and some reporting side effects. The diets were closely monitored by an experienced dietitian and included meal replacements to ensure essential nutrient requirements.

SourceEuropean Association for the Study of Obesity·DateMar 16, 2024